Jones DH - Search Results

1

A molecular and serologic study of the envelope gene of the British isolate: HIV-1 GB8.

Vella C, Smith MH, Farrar GH, Jones DH, Daniels RS. Vella C, et al. Among authors: jones dh. Vaccine. 1995;13(8):735-41. doi: 10.1016/0264-410x(94)00048-r. Vaccine. 1995. PMID: 7483788

2

Purification and characterization of simian immunodeficiency virus (SIVmac) envelope glycoprotein gp130 from virus-infected cells.

Jones DH, McBride BW, Roff MA, Maloney V, Farrar GH. Jones DH, et al. Vaccine. 1994;12(3):250-8. doi: 10.1016/0264-410x(94)90202-x. Vaccine. 1994. PMID: 8165858

3

Efficient purification and rigorous characterisation of a recombinant gp120 for HIV vaccine studies.

Jones DH, McBride BW, Roff MA, Farrar GH. Jones DH, et al. Vaccine. 1995 Aug;13(11):991-9. doi: 10.1016/0264-410x(95)00019-w. Vaccine. 1995. PMID: 8525694

4

Protection of mice from Bordetella pertussis respiratory infection using microencapsulated pertussis fimbriae.

Jones DH, McBride BW, Jeffery H, O'Hagan DT, Robinson A, Farrar GH. Jones DH, et al. Vaccine. 1995 May;13(7):675-81. doi: 10.1016/0264-410x(95)99876-j. Vaccine. 1995. PMID: 7668037

5

Poly(DL-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration.

Jones DH, Corris S, McDonald S, Clegg JC, Farrar GH. Jones DH, et al. Vaccine. 1997 Jun;15(8):814-7. doi: 10.1016/s0264-410x(96)00266-6. Vaccine. 1997. PMID: 9234522

6

Comparison of the immunological and protective responses elicited by microencapsulated formulations of the F1 antigen from Yersinia pestis.

Reddin KM, Easterbrook TJ, Eley SM, Russell P, Mobsby VA, Jones DH, Farrar GH, Williamson ED, Robinson A. Reddin KM, et al. Among authors: jones dh. Vaccine. 1998 May;16(8):761-7. doi: 10.1016/s0264-410x(97)00305-8. Vaccine. 1998. PMID: 9627932

7

A novel microencapsulated peptide vaccine against hepatitis B.

Moynihan JS, Jones DH, Farrar GH, Howard CR. Moynihan JS, et al. Among authors: jones dh. Vaccine. 2001 Apr 30;19(23-24):3292-300. doi: 10.1016/s0264-410x(00)00540-5. Vaccine. 2001. PMID: 11312028

8

Prechallenge high neutralizing antibodies and long-lasting immune reactivity to gp41 correlate with protection of rhesus monkeys against productive simian immunodeficiency virus infection or disease development.

Petry H, Dittmer U, Jones D, Farrar G, Wachter H, Fuchs D, Nisslein T, Jurkiewicz E, Hunsmann G, Stahl-Hennig C, Lüke W. Petry H, et al. J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Dec 15;19(5):441-50. doi: 10.1097/00042560-199812150-00002. J Acquir Immune Defic Syndr Hum Retrovirol. 1998. PMID: 9859957

9

CTL responses induced by a single immunization with peptide encapsulated in biodegradable microparticles.

Partidos CD, Vohra P, Jones D, Farrar G, Steward MW. Partidos CD, et al. J Immunol Methods. 1997 Aug 7;206(1-2):143-51. doi: 10.1016/s0022-1759(97)00102-6. J Immunol Methods. 1997. PMID: 9328577

10

Biodegradable microparticles as a delivery system for measles virus cytotoxic T cell epitopes.

Partidos CD, Vohra P, Anagnostopoulou C, Jones DH, Farrar GH, Steward MW. Partidos CD, et al. Among authors: jones dh. Mol Immunol. 1996 Apr;33(6):485-91. doi: 10.1016/0161-5890(96)00032-6. Mol Immunol. 1996. PMID: 8700164

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

415 results

Search Page

Filters